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Abstract
 
Fas is a cell surface death receptor that signals apoptosis. Several proteins have been identified
that bind to the cytoplasmic death domain of Fas. Fas-associated death domain (FADD), which
 
couples Fas to procaspase-8, and Daxx, which couples Fas to the Jun NH
 
2
 
-terminal kinase
 
pathway, bind independently to the Fas death domain. We have identified a 130-kD ki-
nase designated Fas-interacting serine/threonine kinase/homeodomain-interacting protein ki-
nase (FIST/HIPK3) as a novel Fas-interacting protein. Binding to Fas is mediated by a con-
served sequence in the COOH terminus of the protein. FIST/HIPK3 is widely expressed in
mammalian tissues and is localized both in the nucleus and in the cytoplasm. In transfected cell
lines, FIST/HIPK3 causes FADD phosphorylation, thereby promoting FIST/HIPK3–FADD–
Fas interaction. Although Fas ligand–induced activation of Jun NH
 
2
 
-terminal kinase is im-
paired by overexpressed active FIST/HIPK3, cell death is not affected. These results suggest
that Fas-associated FIST/HIPK3 modulates one of the two major signaling pathways of Fas.
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2
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Introduction
 
Fas (APO-1/CD95) is a member of the TNFR family and
induces apoptosis when cross-linked with Fas ligand (FasL)
 
1
 
(1). The Fas–FasL system has an important role in the im-
mune system, where it is involved in the effector function
of cytolytic T cells and in the downregulation of immune
responses (2). Clustering of Fas upon binding of the mem-
brane-bound form of FasL recruits the bipartite mole-
 
cule Fas-associated death domain (FADD), composed of
an NH
 
2
 
-terminal death effector domain (DED) and a
COOH-terminal DD (death domain). FADD binds to Fas
via homophilic DD–DD interactions and recruits the up-
stream DED-containing caspase-8 to the receptor via
DED–DED interactions. Neighboring caspase-8 mole-
cules within this newly formed death-inducing signaling
complex then proteolytically activate each other and ini-
tiate apoptosis by subsequent cleavage of downstream ef-
fector caspases (caspase-3, -6, and -7).
An alternative pathway of Fas signaling involves the Fas-
binding protein Daxx (3), although these data have been
recently challenged (4). It was proposed that upon Fas acti-
vation, Daxx interacts with and activates a mitogen-acti-
vated protein kinase kinase kinase termed ASK1 (apoptosis
signal-regulating kinase 1), leading to the activation of the
Jun NH
 
2
 
-terminal kinase (JNK) and p38 mitogen-activated
protein kinase pathways (5, 6). JNK has been implicated in
activating apoptosis in vitro and in vivo (7–9), but its func-
tional role in death receptor signaling, as assayed by ex-
pressing dominant negative proteins, has been controversial
(10, 11). JNK activation has also been reported to occur
downstream of caspases via the cleavage and activation of
MEKK1, a JNK kinase kinase (12).
Aside from FADD and Daxx, the intracellular domain of
Fas was reported to interact with several other proteins, in-
cluding FAF-1, FAP-1, SUMO-1/Sentrin, and UBC9.
FAF-1 augments apoptosis when overexpressed in mam-
malian cells (13), in contrast to the phosphatase FAP-1,
which has been proposed to act as an inhibitor of cell death
(14). The ubiquitin-like protein SUMO (15) and its ligase
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UBC9 (16, 17) are involved in the modification of a num-
ber of proteins, thereby targeting them to the nuclear
membrane and certain intranuclear structures (18).
Here we report the identification of a novel Fas-interact-
ing protein that we have named Fas-interacting serine/
threonine (Ser/Thr) kinase (FIST)3. FIST3, which is iden-
tical to homeodomain-interacting protein kinase (HIPK)3,
is a Ser/Thr kinase that is capable of inducing FADD phos-
phorylation. Moreover, FIST/HIPK3 modulates FasL-induced
JNK activation.
 
Materials and Methods
 
Antibodies.
 
Antibodies used for immunoprecipitation, JNK
activation assay, immunofluorescence and Western blot include:
anti-Flag M2 (Sigma-Aldrich), anti-FADD (Signal Transduction
Labs.), anti-Fas C-20 (Santa Cruz Biotechnology, Inc.), anti-
PML (promyelocytic leukemia protein) C7 (a gift of H. de Thé,
Hopital St. Louis, Paris, France), anti–phospho-JNK (New En-
gland Biolabs), peroxidase- or Cy5-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories), peroxidase-con-
jugated anti-IgG1 secondary antibody (Southern Biotechnology
Associates, Inc.), and Alexa-conjugated secondary antibodies
(Molecular Probes). Rabbit polyclonal antibodies were raised
against amino acids (aa) 775–878 (clone 25 isolated from the two-
hybrid screen) of murine (m)FIST/HIPK3 and aa 766–920 of the
rat homologue (a gift of J. Palvimo, Institute of Biomedicine,
Helsinki, Finland).
 
Two-Hybrid Screen.
 
A mouse embryo cDNA library cloned
into the NotI site of the vector pVP16 (19), which codes for fu-
sion proteins of the viral transcription activation domain VP16,
was provided by S. Hollenberg (Vollum Institute, Portland, Ore-
gon). The two-hybrid screen and the generation of cytoplasmic
mutants of Fas were previously described (16).
 
Cloning of FIST/HIPK3 cDNA.
 
A cDNA clone for mFIST/
HIPK3 was isolated from a mouse testis cDNA library (Strat-
agene) using a 
 
32
 
P-labeled DNA fragment (random-primed DNA
labeling kit; Boehringer Mannheim) encoding aa 775–878. Dou-
ble-stranded sequencing revealed an open reading frame of 3,576
nucleotides encoding a protein of 1,192 aa with a putative Ser/
Thr kinase domain. EST clones encoding the human homologue
of murine FIST/HIPK3 were identified in the dbEST database at
the National Center for Biotechnology Information (EST clones
H37893 and R57262) by performing a database search using
mFIST/HIPK3 (http://ncbi.nlm.nih.gov). The accession num-
bers (available from EMBL/GenBank/DDBJ) for the human and
murine FIST/HIPK3 cDNA sequences reported in this paper are
AF305238 and AF305239, respectively.
 
Northern Blot Analysis.
 
Northern blot analysis was performed
using human and mouse multiple tissue and human cancer cell
Northern blots (CLONTECH Laboratories, Inc.) with a 
 
32
 
P-
labeled antisense RNA probe encoding aa 531–658 of hFIST/
HIPK3 or a cDNA probe encoding aa 333–591 of mFIST/
HIPK3 according to the manufacturer’s instructions.
 
Expression Vectors.
 
mFIST/HIPK3 isolated from the mouse
testis cDNA library or fragments containing the kinase domain
(aa 142–608) or the COOH-terminal domain of mFIST/HIPK3
(aa 592–1192) were subcloned into a derivative of the pCR3 ex-
pression vector (Invitrogen), in frame with an NH
 
2
 
-terminal Flag
tag. Mutations of the kinase domain of mFIST/HIPK3 (Lys226
 
fi
 
 Ser, K226S or Asp322 
 
fi
 
 Asn, D322N) were achieved by site
directed mutagenesis with two sequential rounds of PCR, using
 
oligonucleotides containing the target mutation. PCR products
were cloned into pCR-blunt (Invitrogen) and subcloned into the
pCR3-derived expression vector, in frame with an NH
 
2
 
-terminal
Flag. Human Fas cDNA was cloned into pCR3 with or without
an NH
 
2
 
-terminal Flag tag. Vesicular stomatitis virus (VSV)-
tagged mutant FADD lacking aa 202–208 or 191–208, respec-
tively, were generated as described above. The following ex-
pression plasmids were obtained from the indicated sources:
Flag-JNK (C. Widmann, Institute of Cell Biology and Morphol-
ogy, Lausanne, Switzerland) and PML (H. de Thé, Hopital St.
Louis, Paris, France).
 
Immunoprecipitation.
 
293T cells were seeded in 6-cm plates
and transfected for 8–15 h with the calcium phosphate precipita-
tion method (20). Cells were harvested 24–36 h after the onset of
transfection and lysed in lysis buffer containing 0.1% NP-40, 50
mM Tris-HCl, pH 7.4, 150 mM NaCl, and protease inhibitors
(Complete™; Boehringer Mannheim), followed by three freeze–
thaw cycles. After preclearing for at least 1 h on Sepharose 6B
(Amersham Pharmacia Biotech), Flag-tagged proteins were im-
munoprecipitated for at least 2 h with anti-Flag agarose. Immu-
noprecipitates were washed three times in lysis buffer without
protease inhibitors before analysis by SDS-PAGE and Western
blotting.
Sample fractionation with nonionic NP-40 detergent was per-
formed as described (21). In brief, the NP-40–soluble fraction
was separated from the insoluble fraction by centrifugation. The
pellet was washed twice in PBS and after sonication, both the
washed pellet and the initial supernatant were solubilized in SDS
sample buffer containing 100 mM dithiothreitol. For the induc-
tion of apoptosis, Jurkat cells were treated with 100 ng/ml Super-
FasL (Alexis) for 5 h in the presence and the absence of z-VAD-
fmk (50 
 
m
 
M).
 
In Vitro Kinase Assay and Phosphoamino Acid Analysis.
 
Expres-
sion plasmids for wild-type or mutant Flag-tagged mFIST/HIPK3
(full length or kinase domain) were transfected in 293T cells in
10-cm plates. After cell lysis in buffer containing 1% Brij-96, 20
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM
MgCl
 
2
 
, 50 mM NaF,1 mM NaVO
 
4
 
, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/
ml aprotinin, 250 
 
m
 
g/ml pefablock, and 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
, immu-
noprecipitated Flag-tagged proteins were subjected to in vitro ki-
nase assay in 0.05% Brij-96, 1 mM Tris-HCl, pH 7.5, 7.5 mM
NaCl, 25 mM Hepes, pH 7.3, 10 
 
m
 
M MgCl
 
2
 
 in the presence of
10 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP as previously described (22). The presence of
Flag-tagged proteins was confirmed by Western blotting.
For phosphoamino acid analysis, phosphorylated proteins were
separated by SDS-PAGE. Dried bands containing phosphorylated
FIST/HIPK3 were excised and proteins were extracted from the
gel by incubation in 50 mM NH
 
4
 
HCO
 
3
 
, 0.1% SDS, 1% 
 
b
 
-mer-
captoethanol for 10 min at 100
 
8
 
C and 2 h at room temperature.
Proteins were precipitated in presence of 20 
 
m
 
g of RNase A, 15%
TCA for 90 min at 4
 
8
 
C and washed once in 10% TCA and once
in ethanol/ether (1:1) before drying. Proteins were lysed in 6 M
HCl for 70 min at 110
 
8
 
C and 10 min on ice, dried, and resus-
pended in acetic acid/formic acid/H
 
2
 
O (156:44:1,800), pH 1.9,
containing cold phospho-serine, phospho-threonine, and phos-
pho-tyrosine (250 
 
m
 
g/ml each). Samples were analysed by two-
dimensional electrophoresis on cellulose TLC plates (Merck) at
1,600 V in acetic acid/formic acid/H
 
2
 
O (156:44:1,800), pH 1.9,
for the first dimension and at 2,000 V in 5% acetic acid, 0.5% py-
ridine for the second dimension. Standards were revealed with
0.2% ninhydrine in acetone.
 
JNK Activation Assays.
 
For JNK activation assays, transfected
293T cells were treated for 4 h with SuperFasL (Alexis) and lysed
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as described before. Cell lysates were analysed by Western blot-
ting for protein expression and the presence of activated (phos-
phorylated) JNK.
 
Confocal Immunofluorescence Microscopy.
 
293T cells seeded on
glass coverslips in 6-cm plates were transfected. 2 d after transfec-
tion, cells were washed with PBS, fixed with 4% paraformalde-
hyde in PBS, and permeabilized in 0.1% saponin in PBS. After
washing, cells were blocked in PBS containing 0.1% saponin and
2% skim milk, incubated with appropriate primary and secondary
antibodies in blocking buffer, and mounted in fluorsave reagent
(Calbiochem). Confocal microscopy was performed on a ZEISS
Axiovert 100 microscope (ZEISS Laser Scanning Microscope
410) with a 63
 
3
 
 oil objective. To detect Cy5 fluorochrome, a
helium laser was filtered at 633 nm. An argon laser at 488 nm was
used to detect Alexa fluorochrome. Under standard imaging con-
ditions, no signal from one fluorochrome could be detected on
 
the other filter set. Standardized conditions for the pinhole size,
for gain and offset (brightness and contrast), were used for image
capture, and each image was the average of 16 scans.
 
Results and Discussion
 
To identify novel proteins interacting with Fas, we used
the yeast two-hybrid system to screen for proteins that bind
to the cytosolic domain of murine Fas (Ser183 
 
fi
 
 Glu306).
A library of murine embryo cDNA fused to the transcrip-
tion activation domain VP16 (23) was screened for possible
interaction with the Fas bait. 15 positive clones were ob-
tained from 5 
 
3 
 
10
 
6
 
 clones screened. Sequencing of the in-
serts revealed that four inserts corresponded to the murine
SUMO-E2 ligase UBC9 as previously reported (16, 17,
Figure 1. Structure, expression and enzymatic activity of FIST/HIPK3. (A and B) Predicted aa sequence and structural organization of human and
murine FIST/HIPK3. FIST/HIPK3 contains a kinase domain and a PEST sequence, which are linked by a region of z200 aa that was identified to in-
teract with the homeoproteins. The PEST domain overlaps with the interaction site for Fas, UBC9, and the androgen receptor (28). Lys1,185 is pre-
dicted to be an acceptor site for SUMO. For each block of aligned sequences, black boxes indicate aa sequence identity, and gray shading indicates se-
quence similarity through conservative aa substitutions. The kinase domain and the Fas interaction domain are indicated by a solid and hatched line,
respectively. (C) Kinase activity of FIST/HIPK3. Flag-tagged FIST/HIPK3 kinase was immunoprecipitated from 293T cells expressing the kinase do-
main of wild-type or mutated FIST/HIPK3 (Lys226Ser or Asp322Asn) and from control transfectants. The immunoprecipitates were subjected to an in
vitro kinase assay, followed by SDS-PAGE and transfer to nitrocellulose, and the membrane was revealed by autoradiography (top, FIST/HIPK3-P) or
by immunoblot analysis with an anti-Flag-antibody. Bottom panel, phosphorylated FIST/HIPK3 kinase was subjected to SDS-PAGE, and radioactive
bands corresponding to phosphorylated proteins were excised and hydrolyzed as described in Materials and Methods. Phosphoamino acids were resolved
by two-dimensional electrophoresis. Positions of unlabeled internal phosphoamino acid standards are indicated by arrowheads.
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24). Another group of 6 clones contained identical (4
clones) or highly homologous sequences (2 clones) (Fig. 1
A). In the two-hybrid system, the protein fragments (we
named the protein FIST for Fas-interacting Ser/Thr ki-
nase) encoded by the insert of the various clones all
strongly interacted with the complete cytoplasmic domain
of Fas but not with TNFR1, lamin A, LDL receptor, or
poly Ig receptor (not shown). An EMBL/GenBank/DDBJ
search revealed that the sequences of clones 4, 16, 18, and
25 were contained in a murine gene recently identified as
HIPK3, whereas clones 10 and 12 corresponded to murine
HIPK1 (25). We cloned the full-length murine and human
homologue of FIST/HIPK3, whose aa sequences were
found to be more than 90% identical (Fig. 1 B). FIST/
HIPK3 contains an NH
 
2
 
-terminal kinase domain, followed
by the domain that interacts with homeoproteins and a
PEST sequence. For HIPK2, it was demonstrated that it
binds to the SUMO-E2 ligase UBC9 through the PEST
domain and that the protein is consequently modified on a
lysine close to the COOH terminus by the ubiquitin-like
SUMO-1 (21). The Fas-interacting domain of FIST/
HIPK3 (aa 775–868), which was deduced from the original
yeast two-hybrid clones, partly overlaps with the UBC9
binding domain and is highly conserved. Interestingly, this
sequence (and the kinase sequence but not the remainder)
is highly conserved in a sequence found in the 
 
Caenorhabdi-
tis elegans
 
 genome (F20B6). The kinase domain of FIST/
HIPK3 shows extensive sequence homology with the Ser/
Thr kinase YAK1 from 
 
Saccharomyces cerevisiae
 
 (26) and the
minibrain gene that is implicated in learning defects associ-
ated with Down’s syndrome (27).
 
We tested whether the predicted Ser/Thr kinase domain
of murine FIST/HIPK3 was functionally active. The ki-
nase-containing region of FIST/HIPK3 (FIST/HIPK3kin;
aa 142–608), tagged at the NH
 
2
 
 terminus with a Flag
epitope, was expressed in 293T cells, immunoprecipitated
with an anti-Flag antibody, and subjected to an in vitro ki-
nase assay. SDS-PAGE analysis revealed a 
 
32
 
P-labeled 50-
kD band, indicating that FIST/HIPK3 is a protein kinase
that becomes autophosphorylated, in agreement with a re-
cent report on the rat homologue of FIST/HIPK3 (28).
Similar results were obtained with full-length FIST/HIPK3
(data not shown). The kinase activity was impaired when
either of the conserved residues, Lys226 or Asp322, two
invariant residues essential for the enzymatic activity of
protein kinases (29), were mutated to Ser and Asn, respec-
tively (Fig. 1 C). Two-dimensional gel electrophoresis re-
vealed that phosphorylation occurred on Thr and Ser resi-
dues (Fig. 1 C).
FIST/HIPK3 mRNA is widely expressed. Northern
blot analysis revealed that FIST/HIPK3 is constitutively
expressed as a transcript of 
 
z
 
7.5 kb in most human and
murine tissues (Fig. 2, A and C) and in a panel of human
cell lines (Fig. 2 B). In murine (and human, detectable after
longer exposure) testis, an additional transcript of 4.4 kb
was detected. The human FIST/HIPK3 gene is localized
on chromosome 7 (30).
Subcellular localization of FIST/HIPK3 was assessed in
293T cells transiently transfected with either FIST/HIPK3
or kinase-defective FIST/HIPK3 (Fig. 3 A). In agreement
with previous reports on the subcellular localization of
HIPK2, a large part of FIST/HIPK3 was localized to nu-
Figure 2. Expression of FIST/HIPK3. Tissue dis-
tribution of the FIST/HIPK3 transcripts. Northern
blots of various human tissues and tumor cell lines (A
and B) and mouse tissues (C) (CLONTECH Labora-
tories, Inc.) were hybridized with a radioactive probe
of FIST/HIPK3.
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clear bodies, also referred to as PML bodies or nuclear
domain (ND)10, where it colocalized with PML (21).
However, FIST/HIPK3 also showed diffuse cytoplasmic
staining. The kinase-defective mutant of FIST/HIPK3 dis-
played an identical subcellular localization. This localization
pattern was confirmed using cell fractionation studies of
Jurkat T cells where a substantial amount of the kinase was
recovered in the detergent-soluble, nonnuclear fraction
(Fig. 3 B).
To map FIST/HIPK3 and Fas interaction more pre-
cisely, several truncated versions of the Fas cytosolic do-
main (Fig. 4 A) were constructed. In yeast, clone 25/FIST/
HIPK3 (Fig. 1) interacted strongly with the entire cytosolic
domain of Fas (Arg166–Glu306) and with the fragments
that lacked either 17 aa adjacent to the membrane-interact-
ing segment (Ser183–Glu306) or the COOH-terminal 18
aa (Arg166–Asp288) (Fig. 4 A). Weak interaction was ob-
served with Fas containing the 
 
lpr
 
cg 
 
mutation in the DD
that prevents FADD recruitment and thus renders Fas inac-
tive (31). No binding at all was observed with the fragment
of Fas corresponding to the DD (Ile207–Asp288) alone or
with the COOH-terminal 18 aa (Leu289–Glu306). Thus,
efficient binding of FIST/HIPK3 to the cytosolic domain
of Fas requires both a functional DD and part of the mem-
brane proximal segment.
To determine whether FIST/HIPK3 also interacts with
Fas in mammalian cells, both proteins were expressed in
293T cells. Transfection with Flag-tagged FIST/HIPK3
constructs and subsequent immunoprecipitation revealed
that full-length FIST/HIPK3 and its kinase-inactive ver-
sion interacted with Fas. Moreover, the Flag–FIST/HIPK3
COOH-terminal domain (FIST/HIPK3-C; aa 592–1,192),
which includes the segment that interacts with Fas in yeast
(Fig. 1), was able to pull down Fas (Fig. 4 B). In contrast,
no interaction was detectable with the region containing
the kinase domain only. Interestingly, no FIST/HIPK3 was
detected when Fas was immunoprecipitated, suggesting
that overexpression of Fas which triggers signaling leads to
a weakening of the Fas–FIST/HIPK3 interaction.
We next investigated whether FADD would compete
with the binding of FIST/HIPK3 to Fas, as both FADD
and FIST/HIPK3 interact with overlapping segments of
Fas. FADD, Fas, and FIST/HIPK3 were therefore ex-
pressed in 293T cells and while analyzing the data, we
made an interesting observation (Fig. 4 C). In SDS-PAGE,
endogenous or overexpressed FADD always migrates as
two molecular species, which correspond respectively to
the phosphorylated and unphosphorylated protein (32).
Phosphorylation occurs on Ser194 close to the COOH ter-
minus of human FADD (33, 34). The role of FADD phos-
phorylation is not known, and the kinase responsible for
this modification has not been identified. Whenever full-
length FIST/HIPK3 or the kinase domain of FIST/HIPK3
were coexpressed, the phosphorylated FADD species was
predominantly detected, suggesting that FADD was a sub-
strate of FIST/HIPK3. In contrast, no induction of FADD
phosphorylation was seen with kinase-dead FIST/HIPK3.
Phosphorylation occurred at or close to the natural phos-
phorylation site (Ser194), as a mutant FADD lacking aa res-
idues 191–208 (Fig. 4 D) was not phosphorylated. In an in
Figure 3. FIST/HIPK3 is localized in nuclear and cytoplasmic compartments. (A) 293T cells
were transfected with FIST/HIPK3 or kinase-defective FIST/HIPK3 and PML, and their subcellu-
lar localization was determined 48 h after transfection by confocal microscopy using the respective
antibodies. The overlay of PML fluorescence (green) and FIST/HIPK3 fluorescence (red) is shown
in yellow. The cellular localization of FIST/HIPK3 was identical in the absence of cotransfected
PML (data not shown). PC, phase contrast. (B) Fractionation of endogenous FIST/HIPK3. Jurkat
T cells were lysed in NP-40. Cellular extracts were then separated into the NP-40–insoluble (P)
and –soluble (S) fractions and analyzed by Western blot using an anti-FIST/HIPK3 antibody. The
specificity of the antibody was verified in 293T cells transfected with a FIST/HIPK3 expression
vector or a vector control, respectively (two right lanes). The weak band in nontransfected cells
corresponds to endogenous FIST/HIPK3.
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vitro kinase assay, where immunoprecipitated FIST/
HIPK3 was added to purified glutathione 
 
S
 
-transferase–
FADD, incorporation of 
 
32
 
P into FADD was very weak
(data not shown). Thus, phosphorylation of FADD by
FIST/HIPK3 may be indirect via a FIST/HIPK3-activated
kinase. The fact that full-length FIST/HIPK3 was less ac-
tive than the FIST/HIPK3 kinase domain alone can be ex-
plained by different expression levels (full-length FIST/
HIPK3 is usually expressed poorly as compared with the
kinase domain alone; Fig. 4, C and E).
These experiments raised the possibility that FADD is
directly interacting with FIST/HIPK3, and indeed, when
FADD and Flag–FIST/HIPK3 constructs were overex-
pressed in 293T cells, FADD was detected in anti-Flag im-
munoprecipitates (Fig. 4 E). Similar to the FIST/HIPK3–
Fas interaction, the COOH-terminal segment but not the
kinase domain appeared to mediate the FIST/HIPK3–
FADD interaction. FIST/HIPK3 associated only weakly
with FADD in the absence of Fas, suggesting that Fas was
required for the stabilization of the FIST/HIPK3–FADD
complex (Fig. 4 E).
FIST/HIPK3–Fas–FADD interaction was also observed
in cells in which Fas and FADD were not overexpressed
(Fig. 4 F). The formation of the trimolecular complex
composed of transfected Flag-tagged FIST/HIPK3 and en-
dogenous FADD and Fas was only detected with FIST/
HIPK3, which contained the COOH-terminal part. No
FIST/HIPK3 was found to coimmunoprecipitate with Fas
when the complex was precipitated with antibodies to Fas
or via Flag-tagged soluble FasL, in agreement with the data
obtained with cells that overexpress these proteins (data not
shown). Using anti-FIST/HIPK3 antibodies to immuno-
precipitate endogenous FIST/HIPK3, no complex forma-
tion was observed, suggesting that the epitopes recognized
by the antibodies in Western blots are masked in the FIST–
FADD–Fas complex. To ascertain that the observed Fas–
FADD–Flag–FIST/HIPK3 interaction was of physiological
significance, we adjusted the levels of exogenous Flag–
FIST/HIPK3 so that they were only slightly higher than
that of endogenous FIST/HIPK3 (Fig. 4 F).
It is well known that phosphorylated and unphosphory-
lated FADD interact equally well with Fas (Fig. 4 G; refer-
ence 32). In contrast, under conditions where FADD was
not completely phosphorylated by FIST/HIPK3, the phos-
phorylated form was predominant in FIST/HIPK3 immu-
noprecipitates, suggesting that phosphorylation of FADD
induced by FIST/HIPK3 leads to an increased association
of the kinase with FADD (Fig. 4 G).
From the above results, it appears that FIST/HIPK3 is a
protein capable of interacting with a surface receptor but at
the same time also functions as a nuclear protein. This is
reminiscent of Daxx (3), and we therefore investigated
whether the two proteins interact. Daxx and FIST/HIPK3
were coexpressed in 293T cells, and strong binding be-
tween full-length FIST/HIPK3 and the NH
 
2
 
-terminal
portion (aa 1–433) was indeed detected (Fig. 4 H). By con-
trast, the COOH-terminal, Fas-interacting segment of
Daxx (aa 628–740) (3) failed to bind FIST/HIPK3 (data
not shown). Interestingly, binding of FIST/HIPK3 to
Daxx was dependent on the kinase activity of FIST/
HIPK3, as the kinase-dead version of FIST/HIPK3 exhib-
ited a greatly diminished binding activity (Fig. 4 H). The
significance of this observation is presently unclear.
Transient transfection assays were used to examine the
consequences of FIST/HIPK3 overexpression and FADD
phosphorylation on Fas-induced cell death. We found that
death signals were transmitted normally in the presence of
FIST/HIPK3. A second signaling pathway triggered by Fas
leads to the activation of JNK, whose activation can ulti-
mately lead to caspase-8–independent apoptosis (3). This
second activity has been attributed to Daxx, which inter-
acts with the cytoplasmic domain of Fas and whose overex-
pression results in an ASK1-dependent JNK activation (5).
We activated JNK by adding FasL to 293T cells and found
that under these conditions, JNK activation was maximal
4 h after stimulation and was mostly independent of caspase
 
Figure 4.
 
Interaction of FIST/HIPK3 with Fas in yeast and mammals. (A) Several deletion mutations of the cytosolic domain of Fas (TM, transmem-
brane segment of Fas; ID, inhibitory domain, sequence proposed to interact with FAP-1) were cloned as fusion proteins with the DNA binding domain of
Gal4. Interaction of these with the VP16 fusion protein of FIST/HIPK3 (aa 775–878, clone 25; Fig. 1) was tested in a two-hybrid system. 
 
b
 
-galactosidase
activity is indicated. 
 
11
 
, strong reaction (dark blue color); 
 
1
 
, weak interaction (faint blue color); 
 
2
 
, no reaction. (B) Interaction of FIST/HIPK3 with
Fas. 293T cells were cotransfected with expression vectors for Flag-tagged FIST/HIPK3 and Fas as indicated, and anti-Flag immunoprecipitates (IP) were
analyzed for the presence of Fas by immunoblotting using anti-Fas antibody. In this and the subsequent figures (Fig. 4, E–H), the expression levels of the
transfected proteins in cell extracts are shown in the lower panels. (C) FIST/HIPK3 overexpression results in FADD phosphorylation. 293T cells were
transfected with expression vectors for Flag-tagged FIST/HIPK3, and phosphorylation of endogenous FADD was analyzed by Western blotting. The up-
per of the two bands corresponds to phosphorylated FADD.
 
 
 
(D) FIST/HIPK3 induces FADD phosphorylation between aa residues 191 and 201. 293T
cells were cotransfected with expression vectors for Flag-tagged kinase domains of FIST/HIPK3, wild-type FADD, FADD lacking the COOH-terminal
residues 192–208, or FADD lacking residues 202–208. FADD was analyzed by Western blotting. Note that mutant FADD 
 
D
 
192–208 yields only one
phosphospecies. (E) Interaction of FIST/HIPK3 with phosphorylated FADD. 293T cells were cotransfected with expression vectors for Flag-tagged FIST/
HIPK3, FADD, and Fas as indicated, and anti-Flag immunoprecipitates (IP) were analyzed for the presence of FADD or Fas by immunoblotting using an
anti-FADD or anti-Fas antibody. (F) Interaction of FIST/HIPK3 with endogenous FADD and Fas. 293T cells were transfected with the various FIST/
HIPK3 constructs and anti-Flag immunoprecipitates analyzed as described in E. 1 
 
m
 
g of FIST/HIPK3-encoding plasmids was used to transfect 293T cells,
which resulted in protein concentrations that were comparable to that of the endogenous protein (lower panel). (G) Interaction of Fas and FIST/HIPK3
with FADD. Expression vectors for Flag-tagged Fas and FADD were cotransfected into 293T cells, and anti-Flag immunoprecipitates were analyzed for
the presence of FADD by immunoblotting using anti-FADD antibody. Note that phosphorylated and unphosphorylated FADD is associated with Fas,
whereas only the phosphorylated form is found in the IP of FIST/HIPK3. (H) Interaction of FIST/HIPK3 with Daxx requires the kinase activity of FIST/
HIPK3. Binding experiments were done as described above, by overexpressing Flag-tagged FIST/HIPK3 and VSV-tagged Daxx in 293T cells.
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activation, as the general caspase inhibitor z-VAD had little
effect (Fig. 5 A). When FIST/HIPK3 was overexpressed,
JNK activation was severely impaired, but only when the
catalytic site was intact, suggesting that phosphorylation of
an unknown target protein negatively regulates signals that
lead to FasL-induced JNK activation (Fig. 5 B). When
overexpressed, CARDIAK/RIP2 and viral E10 are both
potent inducers of JNK activation (22, 35). The presence
of FIST/HIPK3, however, did not modulate JNK activa-
tion under these conditions (Fig. 5 C), indicating that
FIST/HIPK3 does not modulate all pathways leading to
JNK activation.
In summary, we have identified FIST/HIPK3 as a kinase
that interacts with Fas and FADD. FIST/HIPK3 appears to
belong to a growing family of proteins that shuttle between
the cytoplasm and nuclear PML bodies in a SUMO-depen-
dent manner (18). For HIPK2 it has been shown that
SUMO modification occurs on a lysine close to the
COOH terminus (21) that is conserved in all three HIPKs.
It is therefore likely that such posttranscriptional modifica-
tion also occurs in the FIST/HIPK3 protein, considering
also the physical presence of the molecules required for
SUMO modification (the cytoplasmic domain of Fas has
been previously shown to interact with both the SUMO li-
gase UBC9 and its substrate SUMO). One of several plau-
sible models would predict that Fas-associated FIST/
HIPK3 becomes SUMO modified by UBC9 upon Fas ac-
tivation and subsequently translocates to PML bodies. Al-
though the role of PML bodies remains elusive despite
links to oncogenesis and viral replication, it is noteworthy
that inhibition of PML body formation caused by the dele-
tion of the PML protein suppresses Fas-induced apoptosis
(36). Considering that FIST/HIPKs are also potent repres-
sors of transcription (25), it is tempting to speculate that
FIST/HIPK3 may participate in a Fas-dependent nuclear
 
response. This function is similar to the role suggested for
Daxx, which interestingly is also modified by SUMO and
proposed to shuttle from Fas to the nucleus (3, 37, 38).
Moreover, Daxx interacts with FIST/HIPK3, at least upon
overexpression, and it is therefore likely that the two pro-
teins modulate each other’s activities in a yet undefined
manner.
Additional work is also required to determine the exact
functional significance of the Fas–FADD–FIST/HIPK3 in-
teraction. FADD becomes phosphorylated in the presence
of FIST/HIPK3, and this phosphorylation is important for
FADD–FIST/HIPK3 interaction to occur. In agreement
with other studies, FADD phosphorylation does not appear
to regulate apoptosis, as FasL-induced apoptosis is not af-
fected by FIST/HIPK3 overexpression. Recently, several
uncharacterized Fas-associated Ser/Thr kinase activities
were described that phosphorylate Fas and FADD (39).
One of these kinases exhibits a molecular mass of 
 
z
 
120 kD
and could therefore correspond to FIST/HIPK3. We
found that FasL-mediated JNK activation is impaired by
active FIST/HIPK3, but whether this is due to FADD
phosphorylation remains to be established in future studies.
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